article thumbnail

Impact of IFM 2009 and DETERMINATION Studies

Pharmacy Times

Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients. (..)

65
article thumbnail

Could Higher Doses of Buprenorphine Help People With OUD Stay in Treatment?

Drug Topics

Treatment with buprenorphine has more than doubled since 2009, but dosing guidelines are based on studies with people using heroin that were done before the fentanyl crisis.

201
201
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2022-2023 Influenza Season Classified as High Severity by CDC

Drug Topics

This season marks the fourth to be classified as high severity since the 2009 influenza A(H1N1) pandemic.

187
187
article thumbnail

FDA Approves Iloperidone for Acute Treatment of Manic, Mixed Episodes in Bipolar I

Drug Topics

The drug was previously approved in 2009 to treat schizophrenia.

FDA 154
article thumbnail

Between hope and despair: Improving cancer outcomes

PhRMA

In 2009, there weren’t many treatment options available, and the doctors weren’t sure how to respond because not many Black patients had had similar diagnoses, so there was little information to go forward on. Unfortunately, the tumor was diagnosed late in progression and inoperable.

Hospitals 184
article thumbnail

Pfizer settles 12-year-old lawsuit in alleged pay-for-delay scheme for $39M

Fierce Pharma

In a case so old that it predates Pfizer’s 2009 acquisition of Wyeth, the companies and a class-action group of direct drug purchasers have agreed to

108
108
article thumbnail

STAT+: Jeff Shuren, medical devices head at FDA, to leave the agency

STAT

He became director of the Center for Devices and Radiological Health in 2009 and has served in that position ever since. Shuren, who spent 28 years at the agency, started his FDA career in the Commissioner’s Office in 1998.

FDA 132